Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter Froyman

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
British Journal of Cancer|January 19, 2024
Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgeryChiara Landolfo, Jolien Ceusters, Lil Valentin, et al.
NPJ Precision Oncology|December 11, 2025
ADNEX-AI: automated extraction of ultrasound predictors for interpretable ovarian cancer risk stratificationAxel Geysels, Giulia Garofalo, Stefan Timmerman, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancerJenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, et al.
Radiology|November 6, 2019
O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System CommitteeRochelle F Andreotti, Dirk Timmerman, Lori M Strachowski, et al.
JAMA Oncology|December 15, 2022
External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk GroupsStefan Timmerman, Lil Valentin, Jolien Ceusters, et al.
Iscience|November 10, 2025
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumorsAn Coosemans, Jolien Ceusters, Chiara Landolfo, et al.
BMJ (Clinical Research Ed.)|August 1, 2020
Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort studyBen Van Calster, Lil Valentin, Wouter Froyman, et al.
The Lancet. Oncology|February 10, 2019
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort studyWouter Froyman, Chiara Landolfo, Bavo De Cock, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
British Journal of Cancer|January 19, 2024
Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgeryChiara Landolfo, Jolien Ceusters, Lil Valentin, et al.
NPJ Precision Oncology|December 11, 2025
ADNEX-AI: automated extraction of ultrasound predictors for interpretable ovarian cancer risk stratificationAxel Geysels, Giulia Garofalo, Stefan Timmerman, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancerJenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, et al.
Radiology|November 6, 2019
O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System CommitteeRochelle F Andreotti, Dirk Timmerman, Lori M Strachowski, et al.
JAMA Oncology|December 15, 2022
External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk GroupsStefan Timmerman, Lil Valentin, Jolien Ceusters, et al.
Iscience|November 10, 2025
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumorsAn Coosemans, Jolien Ceusters, Chiara Landolfo, et al.
BMJ (Clinical Research Ed.)|August 1, 2020
Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort studyBen Van Calster, Lil Valentin, Wouter Froyman, et al.
The Lancet. Oncology|February 10, 2019
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort studyWouter Froyman, Chiara Landolfo, Bavo De Cock, et al.
Pageof 5